Q3 2026 psychedelic drug development pipeline bullseye charts map clinical-stage programs, company momentum, and the concentration of targets across indications

Psychedelic drug development in Q3 2026 centers on a visual mapping of clinical and near-clinical programs, showing which companies, compounds, and therapeutic indications are attracting the most attention. Bullseye charts organize the field by development stage and help reveal where capital, trial activity, and strategic focus are clustering. Named psychedelic compounds commonly driving this pipeline include psilocybin, MDMA, LSD, ketamine-related approaches, DMT, ibogaine, 5-MeO-DMT, and mescaline. The underlying focus is not only on individual drugs but on how developers position them for mental health and neurological conditions, differentiate delivery methods, and compete for regulatory progress. Industry tracking of this kind matters because the psychedelic sector changes quickly as programs advance, stall, rebrand, or shift indications. A quarter-by-quarter pipeline view helps clarify market structure, highlights concentration around specific assets, and shows where innovation is broadening beyond the best-known compounds.